Rock Creek Pharmaceuticals Inc  

(Public, NASDAQ:RCPI)   Watch this stock  
Find more results for NASDAQ:STSI
0.938
-0.022 (-2.33%)
Real-time:   11:51AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.94 - 0.98
52 week 0.76 - 9.25
Open 0.98
Vol / Avg. 5,029.00/145,383.00
Mkt cap 10.44M
P/E     -
Div/yield     -
EPS -1.60
Shares 10.87M
Beta 1.70
Inst. own 11%
Nov 9, 2015
Q3 2015 Rock Creek Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 16, 2015
Rock Creek Pharmaceuticals Inc at EBD Group BioPharm America - 4:30PM EDT - Add to calendar
Sep 10, 2015
Rock Creek Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference - 1:45PM EDT - Add to calendar
Aug 10, 2015
Q2 2015 Rock Creek Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -67.94% -333.34%
Return on average equity - -
Employees 10 -
CDP Score - -

Address

2040 Whitfield Avenue, Suite 300
SARASOTA, FL 34243
United States - Map
+1-804-5271970 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rock Creek Pharmaceuticals, Inc. is a pharmaceutical company. The Company is specifically focused on research, development, and commercialization of compounds and formulations targeting inflammatory and neurological disorders. The Company is engage in and advance research and clinical development of pharmaceuticals to provide therapeutic solutions. The Company is engaged in vitro and in vivo ability to modulate the expression of specific inflammatory molecules considered relevant to many chronic inflammatory disease states. The Company has conducted in vitro and in vivo toxicological and pharmacological research on lead drug candidates, and poised to begin first Phase 1 clinical trials. The Company’s research area targets are Osteoarthritis, Ulcerative Colitis, Psoriasis, Smoking Cessation, and Hashimoto's Thyroiditis.

Officers and directors

Michael John Mullan Ph.D., M.D. Chairman of the Board, Office of President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
William L. McMahon Interim Chief Financial Officer, Treasurer
Age: 62
Bio & Compensation  - Reuters
Theodore Jenkins Secretary, Vice President - Corporate Strategy & Development
Bio & Compensation  - Reuters
Lee M. Canaan Independent Director
Age: 58
Bio & Compensation  - Reuters
Sunitha Chundru Samuel Independent Director
Age: 38
Bio & Compensation  - Reuters
Scott P. Sensenbrenner Independent Director
Age: 45
Bio & Compensation  - Reuters